{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:12:43Z","timestamp":1788545563592,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"DOI":"10.1007\/s40273-026-01656-7","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:28:06Z","timestamp":1788542886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bayesian Dynamic Borrowing to Enhance Evidence for New Therapies"],"prefix":"10.1007","author":[{"given":"Sean","family":"Yiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Galactionova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Skedgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Durand","family":"Zaleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sculpher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"3","key":"1656_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/resp.12498","volume":"20","author":"K Feltmate","year":"2015","unstructured":"Feltmate K, Janiszewski PM, Gingerich S, et al. Delayed access to treatments for rare diseases: who\u2019s to blame. Respirology. 2015;20(3):361\u20139.","journal-title":"Respirology"},{"key":"1656_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0755-5","volume":"13","author":"D Whicher","year":"2018","unstructured":"Whicher D, Philbin S, Aronson N. An overview of the impact of rare disease characteristics on research methodology. Orphanet J Rare Dis. 2018;13:14. https:\/\/doi.org\/10.1186\/s13023-017-0755-5.","journal-title":"Orphanet J Rare Dis"},{"issue":"18","key":"1656_CR3","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.21037\/atm-21-5496.PMID:36267797;PMCID:PMC9577738","volume":"10","author":"Y Li","year":"2022","unstructured":"Li Y, Izem R. Novel clinical trial design and analytic methods to tackle challenges in therapeutic development in rare diseases. Ann Transl Med. 2022;10(18):1034. https:\/\/doi.org\/10.21037\/atm-21-5496.PMID:36267797;PMCID:PMC9577738.","journal-title":"Ann Transl Med."},{"issue":"1","key":"1656_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2008.12.009","volume":"206","author":"R Duivenvoorden","year":"2009","unstructured":"Duivenvoorden R, de Groot E, Stroes ES, Kastelein JJ. Surrogate markers in clinical trials\u2014challenges and opportunities. Atherosclerosis. 2009;206(1):8\u201316.","journal-title":"Atherosclerosis"},{"issue":"5","key":"1656_CR5","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/ana.26633","volume":"93","author":"MM Reilly","year":"2023","unstructured":"Reilly MM, Herrmann DN, Pareyson D, Scherer SS, Finkel RS, Z\u00fcchner S, et al. Trials for slowly progressive neurogenetic diseases need surrogate endpoints. Ann Neurol. 2023;93(5):906\u201310.","journal-title":"Ann Neurol"},{"issue":"9","key":"1656_CR6","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1177\/13524585231189671","volume":"29","author":"RA Marrie","year":"2023","unstructured":"Marrie RA, Sormani MP, Apap Mangion S, Bovis F, Cheung WY, Cutter GR, et al. Improving the efficiency of clinical trials in multiple sclerosis. Mult Scler J. 2023;29(9):1136\u201348.","journal-title":"Mult Scler J"},{"key":"1656_CR7","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis [Internet]. London: European Medicines Agency; 2015 [cited 2025 Mar 18]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/03\/WC500185161.pdf. Accessed on April 18th 2026."},{"key":"1656_CR8","unstructured":"FDA draft guidance on Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices. https:\/\/www.fda.gov\/media\/91889\/download. Accessed on April 18th 2026."},{"issue":"4","key":"1656_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1191\/1740774505cn102oa","volume":"2","author":"SN Goodman","year":"2005","unstructured":"Goodman SN, Sladky JT. A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain\u2013Barre. Clin Trials. 2005;2(4):305\u201310.","journal-title":"Clin Trials"},{"issue":"4","key":"1656_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1191\/1740774505cn095oa","volume":"2","author":"JB Greenhouse","year":"2005","unstructured":"Greenhouse JB, Seltman H. Using prior distributions to synthesize historical evidence: comments on the Goodman-Sladky case study of IVIg in Guillain\u2013Barr\u00e9 syndrome. Clin Trials. 2005;2(4):311\u20138.","journal-title":"Clin Trials"},{"key":"1656_CR11","unstructured":"FDA review of benlysta (belimumab) for intravenous infusion in children 5 to 17 years of age with SLE. https:\/\/www.fda.gov\/media\/127912\/download. Accessed on April 18th 2026."},{"issue":"6","key":"1656_CR12","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1080\/10543406.2023.2170405","volume":"33","author":"J Travis","year":"2023","unstructured":"Travis J, Rothmann M, Thomson A. Perspectives on informative Bayesian methods in pediatrics. J Biopharm Stat. 2023;33(6):830\u201343.","journal-title":"J Biopharm Stat"},{"key":"1656_CR13","unstructured":"Cockerham A, Gregory M, Iff J, Smith J, Wolfert D. Implications for rare diseases: NICE guidance and outcomes on implementing bayesian borrowing approaches for external control data. In: Presented at the Professional Society for Health Economics and Outcomes Research (ISPOR) Europe; November 15th, 2023; Copenhagen, Denmark. https:\/\/www.ispor.org\/docs\/default-source\/euro2023\/cockerhamnice-guidanceispor-eu-2023final-01nov2023upload132305-pdf.pdf?sfvrsn=5dbbb37f_0. Accessed on April 18th 2026."},{"key":"1656_CR14","unstructured":"Mackay E, Springford A, Heeg B, Arora P, Thorlund K. Combating sample scarcity: a novel bayesian approach to pediatric basket trials. In: Presented at the Professional Society for Health Economics and Outcomes Research (ISPOR) Europe; November 15th, 2023; Copenhagen, Denmark. https:\/\/www.ispor.org\/docs\/default-source\/euro2023\/isporeurope23mackaymsr82poster133896-pdf.pdf?sfvrsn=eee705e5_0. Accessed on April 18th 2026."},{"key":"1656_CR15","unstructured":"Potts J, Wang M. Application of a novel Bayesian dynamic borrowing approach using anonymized Finnish real-world data as an external control arm to augment an internal control arm of a randomized clinical trial. In: Presented at the Professional Society for Health Economics and Outcomes Research (ISPOR) Europe; November 15th, 2023; Copenhagen, Denmark. https:\/\/www.ispor.org\/docs\/default-source\/intl2024\/ispor24pottsmsr29poster138835-pdf.pdf?sfvrsn=46974e48_0. Accessed on April 18th 2026."},{"issue":"5","key":"1656_CR16","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0175","volume":"13","author":"A Struebing","year":"2024","unstructured":"Struebing A, McKibbon C, Ruan H, Mackay E, Dennis N, Velummailum R, et al. Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer. J Comp Eff Res. 2024;13(5):e230175.","journal-title":"J Comp Eff Res."},{"key":"1656_CR17","unstructured":"FDA draft guidance on the use of Bayesian methodology in clinical trials of drug and biological products. Draft guidance for industry use of bayesian methodology in clinical trials of drug and biological products. https:\/\/www.fda.gov\/media\/190505\/download"},{"key":"1656_CR18","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/sim.8060","volume":"38","author":"G Saint-Hilary","year":"2019","unstructured":"Saint-Hilary G, Barboux V, Pannaux M, Gasparini M, Robert V, Mastrantonio G. Predictive probability of success using surrogate endpoints. Stat Med. 2019;38:1753\u201374.","journal-title":"Stat Med"},{"issue":"4","key":"1656_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/pst.2298","volume":"22","author":"H Quan","year":"2023","unstructured":"Quan H, Xu Z, Luo J, Paux G, Cho M, Chen X. Utilization of treatment effect on a surrogate endpoint for planning a study to evaluate treatment effect on a final endpoint. Pharm Stat. 2023;22(4):633\u201349.","journal-title":"Pharm Stat"},{"key":"1656_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/pst.1589","volume":"13","author":"K Viele","year":"2014","unstructured":"Viele K, Berry S, Neuenschwander B, Amzal B, Chen F, Enas N, et al. Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 2014;13:41\u201354.","journal-title":"Pharm Stat"},{"issue":"1","key":"1656_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11336-022-09869-3","volume":"88","author":"D Kaplan","year":"2023","unstructured":"Kaplan D, Chen J, Yavuz S, Lyu W. Bayesian dynamic borrowing of historical information with applications to the analysis of large-scale assessments. Psychometrika. 2023;88(1):1\u201330.","journal-title":"Psychometrika"},{"key":"1656_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40536-022-00140-w","author":"D Kaplan","year":"2023","unstructured":"Kaplan D, Chen J, Lyu W, et al. Bayesian historical borrowing with longitudinal large-scale assessments. Large-scale Assess Educ. 2023. https:\/\/doi.org\/10.1186\/s40536-022-00140-w.","journal-title":"Large-scale Assess Educ"},{"issue":"4","key":"1656_CR23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/biom.12242","volume":"70","author":"H Schmidli","year":"2014","unstructured":"Schmidli H, Gsteiger S, Roychoudhury S, O\u2019Hagan A, Spiegelhalter D, Neuenschwander B. Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics. 2014;70(4):1023\u201332.","journal-title":"Biometrics"},{"key":"1656_CR24","unstructured":"Welton NJ, Phillippo DM, Owen R, Jones HE, Dias S, Bujkiewicz S, Ades AE, Abrams KR. Nice DSU report: CHTE2020 sources and synthesis of evidence; update to evidence synthesis methods. https:\/\/www.sheffield.ac.uk\/media\/34043\/download?attachment. Accessed on April 18th 2026."},{"issue":"7","key":"1656_CR25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1177\/0272989X18788537","volume":"38","author":"SH Tan","year":"2018","unstructured":"Tan SH, Abrams KR, Bujkiewicz S. Bayesian multiparameter evidence synthesis to inform decision making: a case study in metastatic hormone-refractory prostate cancer. Med Decis Mak. 2018;38(7):834\u201348.","journal-title":"Med Decis Mak"},{"issue":"5","key":"1656_CR26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1037\/met0000602","volume":"30","author":"I Klugkist","year":"2023","unstructured":"Klugkist I, Volker TB. Bayesian evidence synthesis for informative hypotheses: an introduction. Psychol Methods. 2023;30(5):949\u201365.","journal-title":"Psychol Methods"},{"issue":"5","key":"1656_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1177\/0272989X231162852","volume":"43","author":"L Wheaton","year":"2023","unstructured":"Wheaton L, Papanikos A, Thomas A, Bujkiewicz S. Using Bayesian evidence synthesis methods to incorporate real-world evidence in surrogate endpoint evaluation. Med Decis Mak. 2023;43(5):539\u201352.","journal-title":"Med Decis Mak"},{"key":"1656_CR28","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/pst.2093","volume":"20","author":"N Best","year":"2021","unstructured":"Best N, Price RG, Pouliquen IJ, Keene ON. Assessing efficacy in important subgroups in confirmatory trials: an example using Bayesian dynamic borrowing. Pharm Stat. 2021;20:551\u201362.","journal-title":"Pharm Stat"},{"issue":"1","key":"1656_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1214\/088342304000000080","volume":"19","author":"DJ Spiegelhalter","year":"2004","unstructured":"Spiegelhalter DJ. Incorporating Bayesian ideas into health-care evaluation. Stat Sci. 2004;19(1):156\u201374.","journal-title":"Stat Sci"},{"issue":"38","key":"1656_CR30","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/sim.7991","volume":"2019","author":"C R\u00f6ver","year":"2019","unstructured":"R\u00f6ver C, Wandel S, Friede T. Model averaging for robust extrapolation in evidence synthesis. Stat Med. 2019;2019(38):674\u201394.","journal-title":"Stat Med"},{"issue":"3","key":"1656_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"10","key":"1656_CR32","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1177\/13524585221078825","volume":"28","author":"J G\u00e4rtner","year":"2022","unstructured":"G\u00e4rtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, et al. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II. Mult Scler. 2022;28(10):1562\u201375.","journal-title":"Mult Scler"},{"key":"1656_CR33","unstructured":"Biogen. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). ClinicalTrials.gov identifier: NCT01416181. Published August 10, 2011. Updated March 28, 2019. https:\/\/clinicaltrials.gov\/study\/NCT01416181. Accessed on April 18th 2026."},{"key":"1656_CR34","unstructured":"Novartis Pharmaceuticals. A study of fingolimod in primary progressive multiple sclerosis (INFORMS). ClinicalTrials.gov identifier: NCT00731692. Published August 7, 2008. Updated April 12, 2016. https:\/\/clinicaltrials.gov\/study\/NCT00731692. Accessed on April 18th 2026."},{"key":"1656_CR35","unstructured":"Sanofi. Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis. ClinicalTrials.gov identifier: NCT06141486. Published December 1, 2023. Updated January 30, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06141486. Accessed on April 18th 2026."},{"key":"1656_CR36","unstructured":"Sanofi. A study to evaluate the efficacy and safety of tolebrutinib in adult participants with primary progressive multiple sclerosis (PERSEUS). ClinicalTrials.gov identifier: NCT04458051. Published July 8, 2020. Updated January 18, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04458051. Accessed on April 18th 2026."},{"key":"1656_CR37","unstructured":"Hoffmann-La Roche. A study to evaluate the efficacy, safety and pharmacokinetics (pk) of a higher dose of ocrelizumab in adults with relapsing multiple sclerosis (RMS) (MUSETTE). ClinicalTrials.gov identifier: NCT04544436. Published September 9, 2020. Updated March 6, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04544436. Accessed on April 18th 2026."},{"key":"1656_CR38","unstructured":"Hoffmann-La Roche. A study to evaluate the safety and efficacy of ocrelizumab in adults with primary progressive multiple sclerosis (GAVOTTE). ClinicalTrials.gov identifier: NCT04548999. Published September 10, 2020. Updated March 6, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04548999. Accessed on April 18th 2026."},{"key":"1656_CR39","unstructured":"Hoffmann-La Roche. A study to evaluate the efficacy and safety of fenebrutinib compared with teriflunomide in participants with relapsing multiple sclerosis. ClinicalTrials.gov identifier: NCT04458051. Published July 8, 2020. Updated January 18, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04458051. Accessed on April 18th 2026."},{"issue":"1","key":"1656_CR40","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/1352458516638941","volume":"23","author":"D Cadavid","year":"2017","unstructured":"Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, et al. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. 2017;23(1):94\u2013105.","journal-title":"Mult Scler"},{"key":"1656_CR41","doi-asserted-by":"publisher","unstructured":"Kappos L, Yiu S, Dahlke F, Coetzee T, Cutter GR, Yuen S, Bonati U, Lublin FD. Composite confirmed disabilityworsening\/progression is a useful clinical endpoint for multiple sclerosis clinical trials. Neurology. 2025;104(10):e213558. https:\/\/doi.org\/10.1212\/WNL.0000000000213558. Epub 2025 Apr 21. PMID: 40258203; PMCID: PMC12136489.","DOI":"10.1212\/WNL.0000000000213558"},{"issue":"4","key":"1656_CR42","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1212\/WNL.0b013e3181ea15aa","volume":"75","author":"MP Sormani","year":"2010","unstructured":"Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology. 2010;75(4):302\u20139.","journal-title":"Neurology"},{"issue":"9","key":"1656_CR43","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910.","journal-title":"N Engl J Med"},{"key":"1656_CR44","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree B, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263\u201373.","journal-title":"Lancet"},{"issue":"3","key":"1656_CR45","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209\u201320.","journal-title":"N Engl J Med"},{"key":"1656_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/ana.21079","volume":"61","author":"JS Wolinsky","year":"2007","unstructured":"Wolinsky JS, Narayana PA, O\u2019Connor P, Coyle PK, Ford C, Johnson K, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61:14\u201324. https:\/\/doi.org\/10.1002\/ana.21079.","journal-title":"Ann Neurol"},{"key":"1656_CR47","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial\u2020. Ann Neurol. 2009;66:460\u201371. https:\/\/doi.org\/10.1002\/ana.21867.","journal-title":"Ann Neurol"},{"key":"1656_CR48","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/biomet\/68.1.316","volume":"68","author":"D Schoenfeld","year":"1981","unstructured":"Schoenfeld D. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika. 1981;68:316\u20139.","journal-title":"Biometrika"},{"issue":"11","key":"1656_CR49","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/sim.3165","volume":"27","author":"RD Riley","year":"2008","unstructured":"Riley RD, Lambert PC, Staessen JA, Wang J, Gueyffier F, Thijs L, et al. Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med. 2008;27(11):1870\u201393.","journal-title":"Stat Med"},{"key":"1656_CR50","doi-asserted-by":"publisher","unstructured":"Brooks S, Gelman A, Jones G,  Meng XL (Eds.). Handbook of Markov ChainMonte Carlo (1st ed.). Chapman and Hall\/CRC. 2011 https:\/\/doi.org\/10.1201\/b10905","DOI":"10.1201\/b10905"},{"issue":"1","key":"1656_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-14213-6","volume":"22","author":"H Hussein","year":"2022","unstructured":"Hussein H, Nevill CR, Meffen A, Abrams KR, Bujkiewicz S, Sutton AJ, et al. Double-counting of populations in evidence synthesis in public health: a call for awareness and future methodological development. BMC Public Health. 2022;22(1):1827.","journal-title":"BMC Public Health"},{"issue":"3","key":"1656_CR52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/hec.804","volume":"13","author":"NJ Cooper","year":"2004","unstructured":"Cooper NJ, Sutton AJ, Abrams KR, Turner D, Wailoo A. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Econ. 2004;13(3):203\u201326.","journal-title":"Health Econ"},{"key":"1656_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1249611","volume":"14","author":"EK Mackay","year":"2023","unstructured":"Mackay EK, Springford A. Evaluating treatments in rare indications warrants a Bayesian approach. Front Pharmacol. 2023;14:1249611.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1656_CR54","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1177\/0272989X231168618","volume":"43","author":"A Bullement","year":"2023","unstructured":"Bullement A, Stevenson MD, Baio G, Shields GE, Latimer NR. A systematic review of methods to incorporate external evidence into trial-based survival extrapolations for health technology assessment. Med Decis Mak. 2023;43(5):610\u201320.","journal-title":"Med Decis Mak"},{"key":"1656_CR55","unstructured":"European Medicines Agency. Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development. EMA\/CHMP\/138502\/2017. London: European Medicines Agency; 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-statistical-methodology-comparative-assessment-quality-attributes-drug-development_en.pd. Accessed on April 18th 2026."},{"key":"1656_CR56","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Choices in methods for economic evaluation. Saint-Denis La Plaine: HAS; 2020. https:\/\/www.has-sante.fr\/jcms\/p_3216041\/en\/methodological-guidance-2020-choices-in-methods-for-economic-evaluationH. Accessed on April 18th 2026."},{"key":"1656_CR57","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). General Methods: Version 7.0. Cologne: IQWiG; 2023. https:\/\/www.iqwig.de\/methoden\/general-methods_version-7-0.pdf. Accessed on April 18th 2026."},{"key":"1656_CR58","unstructured":"European Commission. Practical guideline for quantitative evidence synthesis: direct and indirect comparisons. Brussels: European Commission; 2023. https:\/\/health.ec.europa.eu\/system\/files\/2023-03\/hta_practical-guideline_direct-and-indirect-comparisons_en_0.pdf. Accessed on April 18th 2026."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01656-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01656-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01656-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:28:08Z","timestamp":1788542888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01656-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":58,"alternative-id":["1656"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01656-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CS and MS are editorial board members of the journal but took no part in the review process or editorial decisions.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S Yiu and KG contributed to the study design, development of the statistical approach, analysis, and interpretation of the simulated data. S Yiu, KG, S Yuen and CS wrote the first draft of the manuscript. All authors critically reviewed the manuscript and suggested or made critical edits to the scientific content of the manuscript.","order":2,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors would like to recognise early input on this work from the cCDP Steering Committee members and Roche contributors. The authors would like to thank Qing Wang, Kristina Weber, Sandro Gsteiger, Aino Launonen, and Claude Berge for helpful discussions that informed the analysis and manuscript. Sean Yiu initiated this work while he was employed by Roche Products Ltd, Welwyn Garden City, UK.","order":3,"name":"Ethics","label":"Acknowledgements","group":{"name":"EthicsHeading","label":"Declarations"}}]}}